Transcode Therapeutics Reports Positive Phase 1a Trial Results for TTX-MC138, Advancing to Phase 2a
RNAZ is trading near its 52-week low of $5.01 (20% below the low).
Summary
Transcode Therapeutics announced successful completion of its Phase 1a clinical trial for TTX-MC138, reporting positive safety and durable disease stabilization in metastatic cancer patients, paving the way for Phase 2a development.
Key Events · Product Development and Regulatory · RNAZ
-
Phase 1a Trial Successfully Completed
The Phase 1a dose escalation clinical trial for TTX-MC138 met its primary endpoint of safety, with no dose-limiting toxicities observed across all dose cohorts.
-
Durable Disease Stabilization Reported
9 out of 14 (64%) evaluable metastatic cancer patients achieved stable disease lasting six months, demonstrating durable disease activity. Three patients remain on trial for extended periods, up to 21 cycles.
-
Advancing to Phase 2a Development
Based on the positive results, Transcode Therapeutics is advancing TTX-MC138 into Phase 2a clinical development to assess efficacy in patients with circulating tumor DNA (ctDNA) positive colorectal cancer.
-
Recommended Phase 2a Dose Selected
The company has selected 4.8mg/kg as the recommended Phase 2a dose (RP2D) for TTX-MC138.
Analysis · RNAZ · Life Sciences
This filing reports crucial positive clinical trial data for Transcode Therapeutics' lead candidate, TTX-MC138. Successfully meeting the primary safety endpoint and demonstrating durable disease stabilization in metastatic cancer patients is a significant de-risking event for a clinical-stage biotech, especially one facing a 'going concern' warning and Nasdaq delisting notices. This positive development is critical for the company's ability to secure future financing and continue operations, potentially shifting investor sentiment from extreme distress to cautious optimism regarding its core asset.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 41.4% of the 440 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RNAZ was trading at $4.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5M. The 52-week trading range was $5.01 to $20.99. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.